mirae asset daewoo

South Korean budget airline applies to list on the stock market as a host of competitors take to the skies.

The sales arm of drug maker Celltrion kicks off Korea's largest share sale this year hoping to match the success of other recent biopharma deals.

An unfavoured sector, unsettled markets and nearly three weeks of secondary market trading risk conspire to push pricing towards the bottom of the private equity firm’s expectations.

Is the private equity-owned group offering a compelling enough story to tempt investors back to a sector which has been on a downswing for well over a year?